{
    "nct_id": "NCT04087018",
    "official_title": "A Phase 1b Study to Evaluate the Safety and Clinical Activity of AB122 in Biomarker-Selected Participants With Advanced Solid Tumors",
    "inclusion_criteria": "* Capable of giving signed informed consent.\n* Male or female participants â‰¥ 18 years of age at the time of screening.\n* Negative serum pregnancy test at screening and negative serum or urine pregnancy test every 3 months during the treatment period (women of childbearing potential only).\n* Pathologically confirmed tumor that is metastatic, advanced, or recurrent with progression for which no alternative known to improve survival or curative therapy exists. Tumors must be TMB-H or Strata Immune Signature positive.\n* Must have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The measurable lesion must be outside of a radiation field if the participant received prior radiation.\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n* Prior chemotherapy or certain immune therapies or biologic agents must have been completed at least 4 weeks (28 days) before investigational product administration and all AEs have either returned to baseline or stabilized.\n* Previously treated brain or meningeal metastases with no evidence of progression by magnetic resonance imaging (MRI) for at least 4 weeks (28 days) prior to the first dose.\n* Immunosuppressive doses of systemic medications, such as corticosteroids or absorbed topical corticosteroids (doses > 10 mg/day prednisone or equivalent) must be discontinued at least 2 weeks (14 days) before investigational product administration. Physiologic doses of corticosteroids < 10 mg/day of prednisone or its equivalent may be permitted\n* Prior surgery that required general anesthesia or other major surgery as defined by the Investigator must be completed at least 4 weeks before investigational product administration\n* Negative tests for hepatitis B surface antigen, hepatitis C virus antibody (or hepatitis C qualitative ribonucleic acid [RNA; qualitative]), and human immunodeficiency virus (HIV)-1 and HIV-2 antibody at screening\n* Adequate organ and marrow function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Use of any live attenuated vaccines against infectious diseases within 4 weeks (28 days) of initiation of investigational product.\n* Underlying medical conditions that, in the Investigator's or Sponsor's opinion, will make the administration of investigational product hazardous or obscure the interpretation of toxicity determination or Adverse events (AEs).\n* History of myocardial infarction within 6 months or history of arterial thromboembolic event within 3 months of the first dose of investigational agent.\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n* Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the pre-screening or screening visit through 90 days after the last dose of investigational product.\n* Any active or documented history of autoimmune disease or history of a syndrome that required systemic steroids or immunosuppressive medications.\n* Any acute gastrointestinal symptoms at the time of screening or admission.\n* Prior malignancy active within the previous year except for locally curable cancers that have been apparently cured.\n* Prior treatment with an anti-PD-L1 or anti-PD-1 as monotherapy or in combination.\n* Prior treatment with temozolomide.\n* Use of other investigational drugs (drugs not marketed for any indication) within 28 days or at least 5 half-lives (whichever is longer) before investigational product administration.",
    "miscellaneous_criteria": ""
}